Stored Fas ligand, a mediator of rapid CTL-mediated killing, has a lower threshold for response than degranulation or newly synthesized Fas ligand

Journal of Immunology

Volumn 184, Issue 2, 2010, Pages 555-563

  He, Jin Shu ^a   Gong, Dong Er ^a   Ostergaard, Hanne L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; FAS LIGAND; ANTIGEN;

ANIMAL CELL; ARTICLE; CELL SURFACE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; ENZYME ACTIVATION; HUMAN; IMMUNE RESPONSE; MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TURNOVER TIME; ANIMAL; BIOSYNTHESIS; BYSTANDER EFFECT; CELL CULTURE; CYTOTOXICITY; DRUG POTENTIATION; IMMUNOLOGY; KINETICS; PROTEIN TRANSPORT;

ANIMALS; ANTIGENS; BYSTANDER EFFECT; CELL DEGRANULATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; KINETICS; MICE; PROTEIN TRANSPORT; T-LYMPHOCYTES, CYTOTOXIC;

EID: 76249113521     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902465     Document Type: Article

References (57)

1. Watanabe-Fukunaga, R., C. I. Brannan, N. Itoh, S. Yonehara, N. G. Copeland, N. A. Jenkins, and S. Nagata. 1992. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148: 1274-1279.
2. Leithäuser, F., J. Dhein, G. Mechtersheimer, K. Koretz, S. Brüderlein, C. Henne, A. Schmidt, K. M. Debatin, P. H. Krammer, and P. Möller. 1993. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 69: 415-429.
3. He, J. S., and H. L. Ostergaard. 2007. CTLs contain and use intracellular stores of FasL distinct from cytolytic granules. J. Immunol. 179: 2339-2348.
4. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science 267: 1449-1456.
5. Askenasy, N., E. S. Yolcu, I. Yaniv, and H. Shirwan. 2005. Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood 105: 1396-1404.
6. Russell, J. H., and T. J. Ley. 2002. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 20: 323-370.
7. Rode, M., S. Balkow, V. Sobek, R. Brehm, P. Martin, A. Kersten, T. Dumrese, T. Stehle, A. Müllbacher, R. Wallich, and M. M. Simon. 2004. Perforin and Fas act together in the induction of apoptosis, and both are critical in the clearance of lymphocytic choriomeningitis virus infection. J. Virol. 78: 12395-12405.
8. Zelinskyy, G., S. Balkow, S. Schimmer, K. Schepers, M. M. Simon, and U. Dittmer. 2004. Independent roles of perforin, granzymes, and Fas in the control of Friend retrovirus infection. Virology 330: 365-374.
9. +-T-cell escape variants of influenza virus. J. Virol. 79: 8545-8559.
10. Ando, K., K. Hiroishi, T. Kaneko, T. Moriyama, Y. Muto, N. Kayagaki, H. Yagita, K. Okumura, and M. Imawari. 1997. Perforin, Fas/Fas ligand, and TNF-α pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J. Immunol. 158: 5283-5291. (Pubitemid 127681233)
11. Balkow, S., A. Kersten, T. T. Tran, T. Stehle, P. Grosse, C. Museteanu, O. Utermöhlen, H. Pircher, F. von Weizsäcker, R. Wallich, et al. 2001. Concerted action of the FasL/Fas and perforin/granzyme A and B pathways is mandatory for the development of early viral hepatitis but not for recovery from viral infection. J. Virol. 75: 8781-8791.
12. Gremion, C., B. Grabscheid, B. Wölk, D. Moradpour, J. Reichen, W. Pichler, and A. Cerny. 2004. Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J. Virol. 78: 2152-2157.
13. Cao, W., S. S. Tykodi, M. T. Esser, V. L. Braciale, and T. J. Braciale. 1995. Partial activation of CD8+ T cells by a self-derived peptide. Nature 378: 295-298.
14. Kessler, B., D. Hudrisier, M. Schroeter, J. Tschopp, J. C. Cerottini, and I. F. Luescher. 1998. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production. J. Immunol. 161: 6939-6946. (Pubitemid 28562241)
15. Kojima, H., M. Toda, and M. V. Sitkovsky. 2000. Comparison of Fas- versus perforin-mediated pathways of cytotoxicity in TCR- and Thy-1-activated murine T cells. Int. Immunol. 12: 365-374.
16. Blakely, A., K. Gorman, H. Ostergaard, K. Svoboda, C. C. Liu, J. D. Young, and W. R. Clark. 1987. Resistance of cloned cytotoxic T lymphocytes to cell-mediated cytotoxicity. J. Exp. Med. 166: 1070-1083.
17. Kane, K. P., and M. F. Mescher. 1993. Activation of CD8-dependent cytotoxic T lymphocyte adhesion and degranulation by peptide class I antigen complexes. J. Immunol. 150: 4788-4797.
18. Durairaj, M., R. Sharma, J. C. Varghese, and K. P. Kane. 2003. Requirement for Q226, but not multiple charged residues, in the class I MHC CD loop/D strand for TCR-activated CD8 accessory function. Eur. J. Immunol. 33: 676-684.
19. Kane, K. P., L. A. Sherman, and M. F. Mescher. 1989. Molecular interactions required for triggering alloantigen-specific cytolytic T lymphocytes. J. Immunol. 142: 4153-4160.
20. Berg, N. N., and H. L. Ostergaard. 1995. Characterization of intercellular adhesion molecule-1 (ICAM-1)-augmented degranulation by cytotoxic T cells: ICAM-1 and anti-CD3 must be co-localized for optimal adhesion and stimulation. J. Immunol. 155: 1694-1702.
21. + T cells. J. Exp. Med. 199: 925-936.
22. Alam, S. M., G. M. Davies, C. M. Lin, T. Zal, W. Nasholds, S. C. Jameson, K. A. Hogquist, N. R. Gascoigne, and P. J. Travers. 1999. Qualitative and quantitative differences in T cell receptor binding of agonist and antagonist ligands. Immunity 10: 227-237.
23. Rosette, C., G. Werlen, M. A. Daniels, P. O. Holman, S. M. Alam, P. J. Travers, N. R. Gascoigne, E. Palmer, and S. C. Jameson. 2001. The impact of duration versus extent of TCR occupancy on T cell activation: a revision of the kinetic proofreading model. Immunity 15: 59-70.
24. Takayama, H., and M. V. Sitkovsky. 1987. Antigen receptor-regulated exocytosis in cytotoxic T lymphocytes. J. Exp. Med. 166: 725-743.
25. Ostergaard, H. L., K. P. Kane, M. F. Mescher, and W. R. Clark. 1987. Cytotoxic T lymphocyte mediated lysis without release of serine esterase. Nature 330: 71-72.
26. 2+ signaling modulates cytolytic T lymphocyte effector functions. J. Exp. Med. 187: 1057-1067.
27. Shen, A., L. G. Puente, and H. L. Ostergaard. 2005. Tyrosine kinase activity and remodelling of the actin cytoskeleton are co-temporally required for degranulation by cytotoxic T lymphocytes. Immunology 116: 276-286.
28. 2+-independent T cell-mediated cytotoxicity. J. Exp. Med. 177: 195-200.
29. Vignaux, F., E. Vivier, B. Malissen, V. Depraetere, S. Nagata, and P. Golstein. 1995. TCR/CD3 coupling to Fas-based cytotoxicity. J. Exp. Med. 181: 781-786.
30. Glass, A., C. M. Walsh, D. H. Lynch, and W. R. Clark. 1996. Regulation of the Fas lytic pathway in cloned CTL. J. Immunol. 156: 3638-3644. (Pubitemid 26137649)
31. Isaaz, S., K. Baetz, K. Olsen, E. Podack, and G. M. Griffiths. 1995. Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur. J. Immunol. 25: 1071-1079.
32. Kuwano, K., and S. Arai. 1996. Involvement of two distinct killing mechanisms in bystander target cell lysis induced by a cytotoxic T lymphocyte clone. Cell. Immunol. 169: 288-293.
33. Smyth, M. J. 1997. Fas ligand-mediated bystander lysis of syngeneic cells in response to an allogeneic stimulus. J. Immunol. 158: 5765-5772.
34. + cytotoxic T lymphocytes. J. Virol. 72: 5948-5954.
35. Hengel, H., and U. H. Koszinowski. 1997. Interference with antigen processing by viruses. Curr. Opin. Immunol. 9: 470-476.
36. Ehrlich, R. 1997. Modulation of antigen processing and presentation by persistent virus infections and in tumors. Hum. Immunol. 54: 104-116.
37. Restifo, N. P., F. Esquivel, Y. Kawakami, J. W. Yewdell, J. J. Mulé, S. A. Rosenberg, and J. R. Bennink. 1993. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177: 265-272.
38. Matsui, M., S. Machida, T. Itani-Yohda, and T. Akatsuka. 2002. Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-γ. J. Gastroenterol. Hepatol. 17: 897-907.
39. + effector T cells supports the idea that lower TCR/epitope avidity may be advantageous for target cell killing. Cell Death Differ. 16: 537-542.
40. Hayes, S. M., L. Li, and P. E. Love. 2005. TCR signal strength influences αβ/γδ lineage fate. Immunity 22: 583-593.
41. Rogers, P. R., and M. Croft. 1999. Peptide dose, affinity, and time of differentiation can contribute to the Th1/Th2 cytokine balance. J. Immunol. 163: 1205-1213.
42. hi T cells. Eur. J. Immunol. 38: 30-39.
43. + T cells. J. Exp. Med. 186: 757-766.
44. Valitutti, S., S. Müller, M. Dessing, and A. Lanzavecchia. 1996. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 183: 1917-1921.
45. Faroudi, M., C. Utzny, M. Salio, V. Cerundolo, M. Guiraud, S. Müller, and S. Valitutti. 2003. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold. Proc. Natl. Acad. Sci. USA 100: 14145-14150.
46. + T cells. Mucosal Immunol. 1: 38-48.
47. Purbhoo, M. A., D. J. Irvine, J. B. Huppa, and M. M. Davis. 2004. T cell killing does not require the formation of a stable mature immunological synapse. Nat. Immunol. 5: 524-530.
48. Huse, M., B. F. Lillemeier, M. S. Kuhns, D. S. Chen, and M. M. Davis. 2006. T cells use two directionally distinct pathways for cytokine secretion. Nat. Immunol. 7: 247-255.
49. + T cells store RANTES in a unique secretory compartment and release it rapidly after TcR stimulation. Immunity 20: 219-230.
50. Kayagaki, N., A. Kawasaki, T. Ebata, H. Ohmoto, S. Ikeda, S. Inoue, K. Yoshino, K. Okumura, and H. Yagita. 1995. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182: 1777-1783.
51. Lettau, M., J. Qian, D. Kabelitz, and O. Janssen. 2004. Activation-dependent FasL expression in T lymphocytes and natural killer cells. Signal Transduct. 4: 206-211.
52. Nguyen, T., and J. Russell. 2001. The regulation of FasL expression during activation-induced cell death (AICD). Immunology 103: 426-434.
53. Itoh, N., A. Imagawa, T. Hanafusa, M. Waguri, K. Yamamoto, H. Iwahashi, M. Moriwaki, H. Nakajima, J. Miyagawa, M. Namba, et al. 1997. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 186: 613-618.
54. Su, X., Q. Hu, J. M. Kristan, C. Costa, Y. Shen, D. Gero, L. A. Matis, and Y. Wang. 2000. Significant role for Fas in the pathogenesis of autoimmune diabetes. J. Immunol. 164: 2523-2532. (Pubitemid 30115482)
55. Qin, H., J. D. Trudeau, G. S. Reid, I. F. Lee, J. P. Dutz, P. Santamaria, C. B. Verchere, and R. Tan. 2004. Progression of spontaneous autoimmune diabetes is associated with a switch in the killing mechanism used by autoreactive CTL. Int. Immunol. 16: 1657-1662.
56. Amrani, A., J. Verdaguer, P. Serra, S. Tafuro, R. Tan, and P. Santamaria. 2000. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 406: 739-742.
57. + T-cell-mediated pathogen control. J. Virol. 81: 11881-11890.